Skip to main content

Table 5 Effect of APO E genotypes on plasma lipid and apolipoprotein profile in control and CAD groups.

From: Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease

Genotype E2/E3 (6 controls, 4 CAD) E3/E3 (25 controls, 38 CAD) E3/E4 (16 controls, 8 CAD) P
*TC     
   Controls 3.48 ± 0.35 4.04 ± 0.49 4.20 ± 0.35 0.005
   CAD 4.04 ± 1.07 4.58 ± 0.62 5.40 ± 0.67 0.007
*TG     
   Controls 0.88 ± 0.10 0.73 ± 0.16 0.83 ± 0.19 0.767
   CAD 1.40 ± 0.77 1.74 ± 0.70 2.11 ± 0.93 0.314
*HDL-C     
   Controls 0.95 ± 0.09 1.12 ± 0.09 1.07 ± 0.13 0.074
   CAD 0.86 ± 0.39 0.92 ± 0.25 0.93 ± 0.28 0.928
*LDL-C     
   Controls 2.12 ± 0.38 2.56 ± 0.46 2.75 ± 0.38 0.014
   CAD 2.55 ± 0.29 2.82 ± 0.70 3.77 ± 0.60 0.017
*Apo A-I     
   Controls 1.33 ± 0.29 1.36 ± 0.16 1.27 ± 0.13 0.797
   CAD 1.10 ± 0.12 1.03 ± 0.14 1.07 ± 0.13 0.939
*Apo B     
   Controls 0.61 ± 0.06 0.73 ± 0.18 0.85 ± 0.16 0.016
   CAD 0.67 ± 0.16 0.98 ± 0.36 1.23 ± 0.29 0.038
*Apo E     
   Controls 57.00 ± 6.07 53.77 ± 6.59 44.62 ± 5.40 0.001
   CAD 56.50 ± 20.74 42.65 ± 9.90 39.37 ± 8.76 0.043
  1. Data is expressed as mean ± SD; P: Probability values obtained by ANOVA for the comparison between E2/E3 and E3/E4 genotype groups.